Open Access

Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells

  • Authors:
    • Peng‑Tao Ren
    • Yuan Zhang
  • View Affiliations

  • Published online on: February 7, 2017     https://doi.org/10.3892/mmr.2017.6175
  • Pages: 1533-1538
  • Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The use of personalized adoptive immunotherapy as a potential novel approach is promising in the treatment of tumors resistant to conventional therapies. In the present study, dendritic cell (DC)‑cytokine‑induced killer (CIK) and DC‑cytotoxic lymphocyte (CTL) cells were cultured to examine their phenotype, proliferation and cytotoxicity against B16 melanoma tumor cells. In addition, comparative investigations of the effect of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells were performed in vitro and in vivo. The results showed that the phenotypes of the co‑cultured cells were altered, and DCs promoted DC‑CIK cell and DC‑CTL cell differentiation and maturation in vitro. Lactate dehydrogenase cytotoxic analysis indicated that the cytotoxicity increased as the effector to target ratio increased between 10:1 and 40:1, and the cytotoxic effect towards B16 melanoma cells by DC‑CTL cells was significantly higher, compared with that of DC‑CIK cells. To further examine the antineoplastic efficacy of DC‑CIK and DC‑CTL cells in vivo, the present study performed tail‑intravenous injection of DC‑CIK cells and DC‑CTL cells, which attenuated B16 melanoma cell‑engrafted tumor growth, induced G0/G1 cell cycle arrest and accelerated cell apoptosis. Taken together, these results suggested that the use of DC‑CTL or DC‑CIK cell therapy as a personalized adoptive immunotherapy may regulate immune status and inhibit tumor growth in vivo. In addition, the experiments indicated that DC‑CTL cells offer superior antineoplastic activity, compared with DC‑CIK cells against B16 melanoma tumor cells.
View Figures
View References

Related Articles

Journal Cover

April-2017
Volume 15 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ren PT and Ren PT: Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells. Mol Med Rep 15: 1533-1538, 2017
APA
Ren, P., & Ren, P. (2017). Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells. Molecular Medicine Reports, 15, 1533-1538. https://doi.org/10.3892/mmr.2017.6175
MLA
Ren, P., Zhang, Y."Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells". Molecular Medicine Reports 15.4 (2017): 1533-1538.
Chicago
Ren, P., Zhang, Y."Comparative investigation of the effects of specific antigen‑sensitized DC‑CIK and DC‑CTL cells against B16 melanoma tumor cells". Molecular Medicine Reports 15, no. 4 (2017): 1533-1538. https://doi.org/10.3892/mmr.2017.6175